All In Biotech

Drug Trial Radar · NCT02160145

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,370 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,370

Actual

Start

May 2014

Primary completion

Apr 18, 2017

Study completion Apr 18, 2017

Sponsor

Sponsor type
Industry
First posted
Jun 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)

Conditions

  • Chronic Kidney Disease
  • Autosomal Dominant Polycystic Kidney Disease

Interventions

  • Tolvaptan (OPC-41061)Drug

    Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.

  • PlaceboDrug

    Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.Time frame: Pretreatment baseline to post-treatment follow-up (up to 61 weeks).

Locations

230 sites in 22 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Hudson, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Lafayette, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Greenbelt, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Wheaton, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Pontiac, Michigan

  • Site not named

    Roseville, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Rochester, Minnesota

  • Site not named

    St Louis, Missouri

Showing 40 of 230 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.